Opdivo (Nivolumab)
Launch:
Opdivo was launched by Bristol-Myers Squibb in 2014.
Manufacturer:
Bristol-Myers Squibb
Global Sales in 2023:
Opdivo achieved global sales of approximately $10 billion in 2023, making it one of the leading immunotherapy drugs.
Why It’s the Best:
Opdivo is a PD-1 inhibitor used in immunotherapy to treat various cancers, including melanoma, non-small cell lung cancer, and renal cell carcinoma.
By blocking the PD-1 pathway, it enables the immune system to better attack cancer cells. Its efficacy in extending survival rates across multiple cancer types has established Opdivo as a critical option in oncology.